 FSD Pharma CSE:HUGE, NASDAQ:HUGE Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide PEA. The Toronto-based biotechnology company said the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 ultramicronized PEA, sponsored by FSD Pharma CSE:HUGE, NASDAQ:HUGE. 